BofA downgraded RxSight (RXST) to Underperform from Buy with a price target of $22, down from $36.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST:
- RxSight’s Growth Potential Amid Challenges: A Buy Recommendation by David Saxon
- RxSight’s Undervaluation and Growth Potential Justify Buy Rating Despite Revenue Shortfall
- RxSight’s Long-Term Growth Potential Justifies Buy Rating Despite Short-Term Challenges
- RxSight sees Q1 revenue $37.9M, consensus $47.0M
- RxSight cuts FY25 revenue view to $160M-$175M from $185M-$197M
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue